Patents Issued in October 17, 2019
  • Publication number: 20190314266
    Abstract: The invention provides a hair treatment composition for the strengthening and/or repair of damaged hair, the composition comprising, in an aqueous continuous phase: (i) one or more oily liquid hair conditioning agents selected from solubilized oily liquid hydrocarbons and mixtures thereof; (ii) a hair substantive cationic conditioning polymer which is a homopolymer of (3-acry-lamidopropyl) trimethyl ammonium chloride, and (iii) a one or more aliphatic carboxylic acids having a molecular weight of 175 g/mol or less, which is a tartaric acid.
    Type: Application
    Filed: November 7, 2017
    Publication date: October 17, 2019
    Inventors: Ningning LI, Arash Mohajer MOGHADAM, Joseph MUSCAT, Susan PYE, Cheryl Anne TAYLOR
  • Publication number: 20190314267
    Abstract: A hair care composition includes a mixture including olive oil, a hair curl controlling cream, unrefined Vitellaria paradoxa (shea) butter and baby oil cream.
    Type: Application
    Filed: April 11, 2018
    Publication date: October 17, 2019
    Inventor: Joyce Turner
  • Publication number: 20190314268
    Abstract: Provided is a mixture of skin oils, that includes white oil, unrefined avocado oil, wheat germ oil, lanolin, and vitamins E, A and D. The mixture of natural enhancement of white oil (USP), as applied to the body, such that the added ingredients upgrade the softening and moisture-retaining characteristics inherent in the basic oil. Natural fragrances may be added. Rancidity does not occur over an indefinite period of time.
    Type: Application
    Filed: April 17, 2018
    Publication date: October 17, 2019
    Inventor: Clarence McGill
  • Publication number: 20190314269
    Abstract: The present application relates to a method of protecting keratinocytes against the effects of air pollution caused by introduction of dust particles, fumes or smoke into the atmosphere such as in particular against the harmful effects of diesel and urban dust particular matter, said method including applying to the skin a cosmetic composition containing an effective amount of an active selected from the group consisting of pullulan and a nannochloropsis occulata extract as well as mixtures thereof.
    Type: Application
    Filed: October 26, 2017
    Publication date: October 17, 2019
    Inventors: Dominik IMFELD, Rolf SCHUETZ, Eliane Ursula WANDELER
  • Publication number: 20190314270
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Application
    Filed: April 15, 2019
    Publication date: October 17, 2019
    Applicant: Rani Therapeutics, LLC
    Inventor: Mir Imran
  • Publication number: 20190314271
    Abstract: The present invention is a topical composition for the treatment of animals, particularly animals in pain, wherein the composition comprises an effective amount of a local anesthetic (e.g., lidocaine) and an analgesic (e.g., meloxicam).
    Type: Application
    Filed: May 17, 2017
    Publication date: October 17, 2019
    Inventor: Merle Olson
  • Publication number: 20190314272
    Abstract: The present invention relates generally to the field of pharmaceutical formulations of antibodies. Specifically, the present invention relates to a stable liquid antibody formulation and its pharmaceutical preparation and use. This invention is exemplified by a liquid formulation of a humanised anti-NGF antibody.
    Type: Application
    Filed: December 14, 2018
    Publication date: October 17, 2019
    Inventors: Advait Vijay Badkar, Leigh Kristen Bohack, Kevin Roger King, Atlanta Lea Lary
  • Publication number: 20190314273
    Abstract: A pharmaceutical hydrocortisone solution including at least hydrocortisone or a pharmaceutically-acceptable salt thereof, rongalite, disodium EDTA, and a solvent. Also relates to its use in the treatment of acute adrenal insufficiency and asthma.
    Type: Application
    Filed: October 25, 2017
    Publication date: October 17, 2019
    Applicant: CROSSJECT
    Inventors: Pauline BARDONNAUD, Frédérique FLORES-IVANEZ
  • Publication number: 20190314274
    Abstract: Disclosed herein is a solid lyophilized vaginal dosage form that can have an effective amount of at least one active ingredient, a crystalline structure forming agent in an amount of about 5 wt. % to about 40 wt. %, based on the total weight of the lyophilized dosage form, and at least one polymeric mucoadhesive matrix forming agent. The dosage form can have a pH of about 4.0 to 5.0, and can disintegrate within 120 seconds after being contacted with a vaginal mucosa. A method of delivering an active ingredient to the vaginal mucosa using the disclosed solid dosage form is also described.
    Type: Application
    Filed: October 13, 2017
    Publication date: October 17, 2019
    Applicant: Catalent U.K. Swindon Zydis Limited
    Inventors: Emilie MASTO, Lisa GARRETT, Niamh BARRAT, Yik Teng WONG, Rosaleen Theresa MCLAUGHLIN, Susan Gerrard BANBURY
  • Publication number: 20190314275
    Abstract: This invention provides compositions comprising a byetta, fish oil, and a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral or rectal administration of a byetta.
    Type: Application
    Filed: June 10, 2019
    Publication date: October 17, 2019
    Applicant: Oramed Ltd.
    Inventor: Miriam Kidron
  • Publication number: 20190314276
    Abstract: Methods are provided for drying a particle. Specifically, there is provided a spray-dried diketopiperazine-insulin particle formulation having improved aerodynamic performance and in which the active agent is more stabile and efficiently delivered as compared to that of the lyophilized diketopiperazine-insulin formulation. The dry powders have utility as pharmaceutical formulations for pulmonary delivery.
    Type: Application
    Filed: June 26, 2019
    Publication date: October 17, 2019
    Inventors: Bryan R. Wilson, Marshall Grant
  • Publication number: 20190314277
    Abstract: Disclosed herein are compositions and methods for treating lung disorders including lung tumors by pulmonary administration of compositions comprising taxane particles such as docetaxel or paclitaxel particles.
    Type: Application
    Filed: June 18, 2019
    Publication date: October 17, 2019
    Inventors: Michael Baltezor, Matthew McClorey, William Johnston, Gere S. diZerega, James Verco
  • Publication number: 20190314278
    Abstract: Disclosed herein is a ready-to-use liquid formulation comprising ropivacaine, epinephrine, clonidine, and ketorolac (collectively referred to as RECK). Also disclosed herein is a process for preparing the RECK-containing liquid formulation, as well as methods for using the same.
    Type: Application
    Filed: April 11, 2019
    Publication date: October 17, 2019
    Applicant: QuVa Pharma, Inc.
    Inventors: Travis A. LEEAH, Jianping CHEN
  • Publication number: 20190314279
    Abstract: Provided herein are stable amlodipine liquid formulations. Also provided herein are methods of using amlodipine liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
    Type: Application
    Filed: April 11, 2019
    Publication date: October 17, 2019
    Inventors: Scott BRAUER, Gerold L. MOSHER
  • Publication number: 20190314280
    Abstract: An aerosol liposome of a marine extract and a method of producing the same are introduced. The marine extract is extracted from cell membranes of marine processing streams, including phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and lysophosphatidylcholine (LysoPC), further including at least phosphatidylserine (PS). The aerosol liposome is of a particle diameter of less than 2,000 nm. The surface of the aerosol liposome carries phosphatidylserine (PS) molecules. The aerosol liposome of a marine extract is simple and stable and can be absorbed through the mouth, nose, upper respiratory tract, and epidermis and engulfed by macrophages therein to quickly alleviate or regulate systematic inflammatory responses and prevent inflammation-related diseases.
    Type: Application
    Filed: May 28, 2019
    Publication date: October 17, 2019
    Inventors: YI-FENG KAO, YI-CHEN CHEN, CHWEN-HERNG WU
  • Publication number: 20190314281
    Abstract: The present invention discloses a novel local anesthetic analgesic sustained-release drug delivery system. The system includes an internal aqueous phase, an external aqueous phase, an oil phase, an organic solvent, an isoosmotic regulator and a pH regulator. The internal aqueous phase includes an analgesic, a drug solvent and a drug solubilizer. The analgesic is selected from one of bupivacaine, levobupivacaine, ropivacaine, lidocaine and tetracaine, and the analgesic is in a free base form or an acid saline form; the drug solvent is selected from inorganic acid containing N or P; and the drug solubilizer is selected from one or more of saccharide and ring-shaped organic acid. The multivesicular liposome prepared in the present invention has the advantages of high encapsulation percentage and drug loading capacity, uniform grain size, and good sustained-release effect.
    Type: Application
    Filed: August 21, 2018
    Publication date: October 17, 2019
    Inventors: Yufan Ma, Tao Chen, Danfeng Kong
  • Publication number: 20190314282
    Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).
    Type: Application
    Filed: June 27, 2019
    Publication date: October 17, 2019
    Inventors: Mark E. HAYES, Charles O. NOBLE, Francis C. SZOKA, JR.
  • Publication number: 20190314283
    Abstract: The invention relates to granules and pharmaceutical compositions comprising a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant obtained by mixing hereof for more than 5 minutes prior to granulation as well as processes for their preparation and use thereof in medicine.
    Type: Application
    Filed: May 10, 2019
    Publication date: October 17, 2019
    Inventor: Thomas Vilhelmsen
  • Publication number: 20190314284
    Abstract: Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g. as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent transfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.
    Type: Application
    Filed: June 25, 2019
    Publication date: October 17, 2019
    Inventors: Braydon Charles Guild, Michael Heartlein, Frank DeRosa, Jerry Chi Zhang
  • Publication number: 20190314285
    Abstract: Disclosed are solid oral dosage forms comprising about 500 mg of abiraterone acetate; and a film coating that is positioned on an outer surface of said dosage form, wherein the dosage forms are bioequivalent to 250 mg ZYTIGA® abiraterone acetate dosage forms when administered orally on an equivalent dose basis. Also disclosed are approved drug products comprising 500 mg abiraterone acetate, as are methods of treatment, of reducing pill burden, and of providing pharmaceutical regimen that is bioequivalent to 250 mg ZYTIGA® abiraterone acetate dosage forms when administered orally on an equivalent dose basis.
    Type: Application
    Filed: April 10, 2019
    Publication date: October 17, 2019
    Inventors: Jurgen Mensch, Urbain Alfons C. Delaet, Philip Erna H. Heyns, Claire Elisabeth Balmain
  • Publication number: 20190314286
    Abstract: The present invention includes acidifying film coating compositions containing a polymer and an acidic component for use on orally-ingestible substrates such as tablets and the like. The acidifying coating compositions can be applied as an aqueous dispersion to an enteric-coated substrate to increase the disintegration resistance to aqueous media of up to pH 5.0. In preferred aspects, the acidic component is citric acid, lactic acid, stearic acid or mixtures thereof. Methods of preparing the dry film coatings, methods of preparing corresponding aqueous dispersions, methods of applying the coatings to substrates and the coated substrates themselves are also disclosed.
    Type: Application
    Filed: March 29, 2019
    Publication date: October 17, 2019
    Applicant: BPSI Holdings LLC
    Inventors: Raxitkumar Y. Mehta, George Reyes, Jason Teckoe, Daniel To
  • Publication number: 20190314287
    Abstract: A method for packaging a lipid compound for ingestion by a human or animal body, comprising the following steps: filling (I) a first part of a prefabricated capsule, previously opened in two parts, with a predetermined volume of a lipid compound; introducing (II) a food-grade lipophilic absorbent into the lipid compound (4) within this first part, so as to produce, after absorption of the lipid compound, a core in the form of a pasty mixture providing for a predetermined dissolution rate, closing (III) the capsule by fitting the second part on the first part containing the core; and coating the capsule thus closed with a polymer, so as to allow subsequent release of the lipid compound at a predetermined release site within said human or animal body.
    Type: Application
    Filed: December 21, 2017
    Publication date: October 17, 2019
    Inventors: Bernard Jacques Kurdyk, Jean-Pierre Lablanchy
  • Publication number: 20190314288
    Abstract: Disclosed are porous polymer microspheres for preventing or treating soft tissue diseases including a biodegradable polymer scaffold having a three-dimensional network structure in which pores having a size of 5 to 100 ?m are connected to one another, and a drug for treating soft tissue diseases incorporated in the network structure of the biodegradable polymer scaffold.
    Type: Application
    Filed: May 4, 2017
    Publication date: October 17, 2019
    Applicants: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, ORTHO HEAL CO., LTD.
    Inventors: Hae-Ryong SONG, Jae Young LEE, Sungeun KIM, Hak Jun KIM, Young-Pil YUN
  • Publication number: 20190314289
    Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.
    Type: Application
    Filed: January 22, 2018
    Publication date: October 17, 2019
    Inventors: Frank Matthews, Garth Boehm, Lijuan Tang, Alfred Liang
  • Publication number: 20190314290
    Abstract: There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.
    Type: Application
    Filed: May 24, 2019
    Publication date: October 17, 2019
    Inventors: Ricardo Alberto VARGAS RINCON, Joseph REIZ
  • Publication number: 20190314291
    Abstract: The disclosure features immune cell delivery lipid nanoparticle (LNP) compositions that allow for enhanced delivery of agents, e.g., nucleic acids, such as therapeutic and/or prophylactic RNAs, to immune cells, in particular T cells, as well as B cells, dendritic cells and monocytes. The LNPs comprise an effective amount of an immune cell delivery potentiating lipid such that delivery of an agent by an immune cell delivery LNP is enhanced as compared to an LNP lacking the immune cell delivery potentiating agent. Methods of using the immune cell delivery LNPs for delivery of agents, e.g., nucleic acid delivery, for protein expression, for modulating immune cell activity and modulating immune responses are also disclosed.
    Type: Application
    Filed: January 30, 2019
    Publication date: October 17, 2019
    Inventors: Gilles BESIN, Luis BRITO, Stephen G. HOGE, Edward HENNESSY, Mark CORNEBISE, Kerry BENENATO, Staci SABNIS, Michael W. DANNEMAN
  • Publication number: 20190314292
    Abstract: The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
    Type: Application
    Filed: April 12, 2019
    Publication date: October 17, 2019
    Inventors: Kerry E. BENENATO, Ellalahewage Sathyajith KUMARASINGHE, Mark CORNEBISE
  • Publication number: 20190314293
    Abstract: A loxapine film oral dosage form includes loxapine salt, free base, or prodrug in an amount effective to provide relief from acute agitation associated with schizophrenia or bipolar 1 disorder via oral transmucosal delivery, dispersed in a polymeric film forming system. Advantageously, the film oral dosage form further includes a sweetener, a refreshing agent, an antioxidant, a pH stabilizer, a penetration enhancer, a mucoadhesive agent and a plasticizer. The loxapine film oral dosage form provides rapid onset of relief from acute agitation associated with schizophrenia or bipolar 1 disorder without presenting pulmonary health risks, thereby reducing risks to patients and others.
    Type: Application
    Filed: June 28, 2019
    Publication date: October 17, 2019
    Applicant: Intelgenx Corp.
    Inventors: Mobarik Bilal, Rodolphe Obeid, Nadine Paiement
  • Publication number: 20190314294
    Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a nom-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.
    Type: Application
    Filed: May 23, 2019
    Publication date: October 17, 2019
    Applicants: UCB Pharma GmbH, LTS Lohmann Therapie-Systeme AG
    Inventors: Hans-Michael WOLFF, Christoph ARTH, Luc QUERE, Walter MÜLLER
  • Publication number: 20190314295
    Abstract: Disclosed is a method of reducing the appearance of a fine line or wrinkle on skin. The method can include topically applying to the fine line or wrinkle a composition comprising an effective amount of 1,4-dioxacycloheptadecane-5,17-dione and methyl 3-oxo-2-pentylcyclopentanecarboxylate to reduce matrix metalloprotease (MMP)-9 activity in the skin, wherein topical application of the composition reduces MMP-9 activity in the skin and reduces the appearance of the fine line or wrinkle on the skin.
    Type: Application
    Filed: June 25, 2019
    Publication date: October 17, 2019
    Inventors: Bob WALKE, Cristie GOMEZ, Tiffany CARLE, Michelle HINES
  • Publication number: 20190314296
    Abstract: The present invention relates to parenteral cannabinoid formulations, and more particularly to cannabinoid containing intravenous (IV) formulations. Preferably the parenteral containing formulation comprises a cannabinoid; an isotonic agent; a surfactant; and one or more stability enhancers. Furthermore the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerolpropyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA).
    Type: Application
    Filed: June 29, 2017
    Publication date: October 17, 2019
    Inventors: Stephen Wright, Jitinder WILKHU
  • Publication number: 20190314297
    Abstract: Provided are concerns and methods of using glatiramer acetate (GA) and cannabidiol (CBD), for treating, preventing, ameliorating or delaying MS, and side effects associated with MS treatment.
    Type: Application
    Filed: November 2, 2017
    Publication date: October 17, 2019
    Applicant: TO PHARMACEUTICALS LLC
    Inventor: Ruth GALLILY
  • Publication number: 20190314298
    Abstract: The present invention is a beverage for relieving and preventing harmful effects of alcohol consumption such as hangover and liver cell damage, which includes Curcuma longa Rhizome extract, L-Ornithineamino acid, and Inositol as active ingredients. The curcumin extracts standardized to ?95% pure curcuminoids having at least 12% in the form of water-dispersible micelle liquid or at least 10% in the form of nanosuspension. A method for beverage composition includes a defined amount of curcumin extract, L-Ornithine Inositol, and sugar syrup, wherein the curcumin extract, L-Ornithine and Inositol Powder added to the separately prepared sugar syrup under constant stirring. The present invention accelerates In vivo decomposition of alcohol after drinking, thereby helping to relieve and prevent harmful effects of alcohol such as hangover and liver damage.
    Type: Application
    Filed: April 12, 2019
    Publication date: October 17, 2019
    Inventor: Vasu Goyal
  • Publication number: 20190314299
    Abstract: The present invention describes stable topical barrier compositions comprising primary polyamines and uses thereof for protecting the skin from external stressors, for improving skin's moisture and fort stimulating healing of the skin. These compositions may be used in a variety of cosmetic and therapeutic applications including for promoting wound healing, for reducing or preventing the formation of hypertrophic scar tissue, for reducing or preventing skin irritation and inflammation, for increasing skin's moisture and/or for reducing or preventing skin's signs of aging.
    Type: Application
    Filed: January 5, 2018
    Publication date: October 17, 2019
    Inventor: GHISLAIN VIVIER
  • Publication number: 20190314300
    Abstract: The invention is a method of treating a subject with primary progressive or secondary progressive multiple sclerosis. The method comprises administering an effect amount of Cis-N-cyclohexyl-N-ethyl-3-(3-chloro-4-cyclohexylphenyl)prop-2-enylamine or a pharmaceutically acceptable salt thereof to the subject.
    Type: Application
    Filed: December 21, 2018
    Publication date: October 17, 2019
    Inventors: Paul Tesar, Drew Adams, Steven B. Landau
  • Publication number: 20190314301
    Abstract: There is herein provided pharmaceutical formulations and kits-of-parts comprising a ?2-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, and a ?3-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof. This combination of active agents finds particular utility in the treatment of type 2 diabetes.
    Type: Application
    Filed: July 13, 2017
    Publication date: October 17, 2019
    Applicant: Atrogi AB
    Inventors: Benjamin PELCMAN, Tore BENGTSSON
  • Publication number: 20190314302
    Abstract: Compounds for use in methods of treating, preventing, or ameliorating pulmonary hypertension; reducing glutamine metabolism in a patient in need thereof, and/or increasing SIRT3 activity in a patient in need thereof.
    Type: Application
    Filed: November 15, 2017
    Publication date: October 17, 2019
    Inventors: Joshua P. Fessel, L. Jackson Roberts, II, James West
  • Publication number: 20190314303
    Abstract: A method for the treatment or prevention of a cardiovascular event in a subject with atherosclerotic vascular disease comprising the step of: b) administering a therapeutically effective amount of a compound of formula (I), a known colchicine derivative and/or a salt thereof wherein: R1, R2, R3, R4, R9, R10, R11 and R12 independently represent hydrogen, C1-4 alkyl, C2-4 alkenyl, C3-6 cycloalkyl, halogen, C1-4 haloalkyl, nitro, amino, C2-4 acylamino, C1-4 alkyl or dialkylamino, hydroxyl, C1-4 alkoxy, C1-4 alkylthio, a group of the formula —SO2N(Rx)2 or SO2Rx where Rx is C1-4 alkyl, C1-4 acyloxy, or optionally substituted phenyl, optionally substituted phenoxy; R7 and R8 independently represent hydrogen, C1-4 alkyl or C1-4 acyl; and R5?, R5?, R6? and R6? independently represent hydrogen, C1-4 alkyl, C2-4 alkenyl, C3-6 cycloalkyl, halogen, C1-4 haloalkyl, nitro, amino, C2-4 acylamino, hydroxyl, C1-4 alkoxy or C1-4 alkylthio a group of the formula —SO2N(Rx)2 or SO2Rx where Rx is C1-4 alkyl, C1-4 acyl
    Type: Application
    Filed: April 22, 2019
    Publication date: October 17, 2019
    Inventor: Mark Nidorf
  • Publication number: 20190314304
    Abstract: The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II): wherein R1, R2, R3, X and Y are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I): wherein R2, R3, and X, are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.
    Type: Application
    Filed: October 31, 2018
    Publication date: October 17, 2019
    Inventor: Hilde Steineger
  • Publication number: 20190314305
    Abstract: A method is provided for treating a subject in need of medication as an adjunct to elective surgery, comprising administration of a ketogenic material sufficient to produce a physiologically acceptable ketosis in tile patient. Preferably the surgery is selected from the groups consisting of removal or section of tumours, removal of redundant organs such as lymph nodes and appendix, open heart surgery, cosmetic surgery, joint and bone surgery.
    Type: Application
    Filed: April 16, 2019
    Publication date: October 17, 2019
    Inventors: David John Heal, Keith Frank Martin
  • Publication number: 20190314306
    Abstract: The present invention generally relates to systems and methods for treating vitiligo. In one set of embodiments, the present invention comprises a composition comprising pyruvic acid and/or a pyruvate salt. The composition may be formulated for application to the skin of a subject, for instance, as a gel, lotion, cream, ointment, soap, or stick. In some cases, the composition may comprise a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present as a liquid crystal, and/or in liposomes, micelles, or other vesicles. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Application
    Filed: April 23, 2019
    Publication date: October 17, 2019
    Applicant: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Publication number: 20190314307
    Abstract: This invention relates generally to methods and compositions for the treatment or prevention of critical illness myopathy and critical illness polyneuropathy and of critical illness myopathy and critical illness polyneuropathy caused by critical illnesses including sepsis, severe sepsis, severe sepsis with septic shock, and particularly to the use of a combination of parenteral or enteral feeding with a 3-hydroxybutyrate.
    Type: Application
    Filed: December 4, 2017
    Publication date: October 17, 2019
    Inventors: Chloe Goossens, Lies Langouche, Greet Van Den Berghe, Ilse Vanhorebeek
  • Publication number: 20190314308
    Abstract: Described herein is the use of sulindac in the treatment of fragile X syndrome (FXS).
    Type: Application
    Filed: April 12, 2019
    Publication date: October 17, 2019
    Inventor: David Brown
  • Publication number: 20190314309
    Abstract: Described herein are kits, compositions, and combination therapies comprising sulindac for use in the treatment of fragile X syndrome (FXS).
    Type: Application
    Filed: April 12, 2019
    Publication date: October 17, 2019
    Inventor: David Brown
  • Publication number: 20190314310
    Abstract: A method of delivering a daily dose of hydroxycitric acid in the form of a salt as a single bolus that is as effective or more so than the same amount of active delivered via two or three administrations (b.i.d. or t.i.d.) using current delivery modalities. The method reduces the rate of occurrence of common adverse events with hydroxycitric acid salts, and reduces the occurrence of reverse effects on diets high in fat and/or alcohol. The method improves the uptake of the active compound thereby reducing the dose required.
    Type: Application
    Filed: June 25, 2019
    Publication date: October 17, 2019
    Inventors: Dallas L. CLOUATRE, Daniel E. CLOUATRE, Brad J. DOUGLASS
  • Publication number: 20190314311
    Abstract: The present invention provides a pharmaceutical composition effective for treatment of the PolyQ diseases, which can be safely administered to humans. The present invention provides a pharmaceutical composition comprising: one selected from the group consisting of arginine, a physiologically acceptable salt thereof, and a solvate thereof, as an active ingredient, in which the pharmaceutical composition is used in treatment or prevention of the PolyQ diseases, and the the PolyQ disease is one selected from the group consisting of Huntington disease, inherited spinocerebellar ataxias, dentatorubral palliodoluysian atrophy, and spinal bulbar muscular atrophy.
    Type: Application
    Filed: June 23, 2017
    Publication date: October 17, 2019
    Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Yoshitaka Nagai, Helena Akiko Popiel, Eiko Minakawa
  • Publication number: 20190314312
    Abstract: Provided are uses of a therapeutically effective amount of citrulline for the manufacture of a medicament for treatment of a subject having an inflammatory bowel disease (IBD) and/or colon cancer. Also provided are pharmaceutical compositions comprising a therapeutic effective amount of citrulline and a therapeutically effective amount of a flavonoid for the treatment of an inflammatory bowel disease (IBD) and/or colon cancer and kits comprising same.
    Type: Application
    Filed: July 11, 2017
    Publication date: October 17, 2019
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Ayelet EREZ, Noa STETTNER
  • Publication number: 20190314313
    Abstract: Disclosed herein are methods and compositions for the production of L-3,4-dihydroxyphenylalanine from a bacteria.
    Type: Application
    Filed: October 11, 2017
    Publication date: October 17, 2019
    Inventors: Andrew D. Ellington, Ross Thyer
  • Publication number: 20190314314
    Abstract: Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward thyroid hormone ?v?3 integrin receptor antagonists conjugated to targets of the norepinephrine transporter (NET) or the catecholamine transporter. The compositions have a dual targeting effect and increased targeting efficiency in the treatment and diagnostic imaging of neuroendocrine tumors.
    Type: Application
    Filed: April 30, 2019
    Publication date: October 17, 2019
    Inventors: Shaker Mousa, Mehdi Rajabi, Ozlem O. Karakus
  • Publication number: 20190314315
    Abstract: The present invention relates generally to methods for the treatment and/or prophylaxis of neurological diseases and disorders involving administration of trans 10-HDA. In particular, the methods of the present invention are useful in the treatment and/or prophylaxis of acquired or progressive neurodevelopmental disorders and conditions in mammals. More particularly, methods are taught herein for the treatment and/or prophylaxis of diseases and disorders such as autism spectrum disorders.
    Type: Application
    Filed: February 22, 2019
    Publication date: October 17, 2019
    Inventors: Steve CHEUNG, Wah Chin BOON